Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ: CCCC )

7.840 +0.180 (+2.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 218,251
Open 7.640
Bid (Size) 7.840 (20)
Ask (Size) 7.860 (46)
Prev. Close 7.660
Today's Range 7.470 - 7.980
52wk Range 4.840 - 26.80
Shares Outstanding 48,797,226
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
From C4 Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
+22.88%
+22.88%
1 Month
+36.11%
+36.11%
3 Month
-18.50%
-18.50%
6 Month
-17.30%
-17.30%
1 Year
-64.89%
-64.89%

More News

Read More
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via Globe NewsWire
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
C4 Therapeutics's Return On Capital Employed Overview
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points
Via Benzinga
C4 Therapeutics: Q3 Earnings Insights
Via Benzinga
Recap: C4 Therapeutics Q2 Earnings
Via Benzinga
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Via Benzinga
Credit Suisse, Autodesk And Other Big Losers From Wednesday
Via Benzinga
C4 Therapeutics: Q1 Earnings Insights
Via Benzinga
Where C4 Therapeutics Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Via Benzinga
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Via Benzinga
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
From C4 Therapeutics, Inc.
Via Globe NewsWire
C4 Therapeutics's Return On Capital Employed Insights
Via Benzinga
C4 Therapeutics's Return On Capital Employed Overview
Via Benzinga
C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers
Via Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Via Benzinga
66 Biggest Movers From Yesterday
Via Benzinga
31 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.